Sorafenib bulk supplier for pharma manufacturers

Sorafenib 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 200 mg

Reference Brands: Nexavar (US & EU)

Sorafenib is an oral kinase inhibitor used to treat advanced liver cancer (HCC), renal cell carcinoma (RCC), and thyroid cancer. Available in 200 mg tablets under the brand Nexavar® in the US and EU, it blocks tumor cell growth and angiogenesis. Ideal for B2B pharma distributors.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Sorafenib? List it or send an offer →

Product Description:

Sorafenib is a targeted therapy used in the treatment of advanced liver cancer (HCC), renal cell carcinoma (RCC), and thyroid cancer. As an oral kinase inhibitor, it works by blocking tumor cell proliferation and angiogenesis. Available under the brand name Nexavar®, it is marketed in 200 mg tablets in both the US and EU. Sorafenib is a critical component in the treatment of various solid tumors and is manufactured under GMP-compliant standards. Ideal for B2B pharmaceutical partners, it is supplied globally for oncology distributors and hospital tender markets seeking reliable oncology treatments.

Sorafenib — third party manufacturing & bulk supply

Sorafenib 200 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Sorafenib is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Sorafenib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Sorafenib →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Sorafenib tosylate is used for the treatment of certain types of cancer, including hepatocellular carcinoma (liver cancer), advanced renal cell carcinoma (kidney cancer), and radioactive iodine-refractory differentiated thyroid carcinoma. It works by slowing tumor cell growth and reducing tumor blood vessel formation.

Sorafenib is made from the active pharmaceutical ingredient sorafenib tosylate, a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis by targeting multiple intracellular and cell surface kinases.

The main international trade name is Nexavar.

The original branded product Nexavar is developed and marketed by Bayer. Generic sorafenib products are manufactured by multiple pharmaceutical companies worldwide after patent expiry in several regions.

The complete generic name is sorafenib tosylate.

The primary brand name is Nexavar.

Sorafenib tablets are manufactured in multiple countries including the USA, EU, UK, and India by Bayer and various GMP-certified generic manufacturers for global oncology supply.